UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) Commission file number: 001-11993 OPTION CARE HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 05-0489664 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: 312-940-2443 Securities regis ...

PLEASANTON, Calif., February 24, 2026 – Workday, Inc. (NASDAQ: WDAY), the enterprise AI platform for managing people, money, and agents, today announced results for the fiscal 2026 fourth quarter and full year ended January 31, 2026. Fiscal 2026 Fourth Quarter Results Fiscal Year 2026 Results See the section titled "About Non-GAAP Financial Measures" in the accompanying financial tables for further details. 1 Exhibit 99.1 Workday Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results Fiscal Fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file numbe ...

Financial Results - Tempus AI, Inc. reported preliminary financial results for Q4 and full year 2025 on January 11, 2026[6] - The total remaining contract value as of December 31, 2025, was disclosed in a press release on January 11, 2026[8] Corporate Communication - The company made an updated corporate presentation available on its investor relations website on January 11, 2026[9]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 Registrant's telephone number, including area code (414) 354‑2310 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-34728 DOUGLAS DYNAMICS, INC. (Exact name of registra ...

Financial Performance - Generated $0.33 per common share of net investment income and $0.36 per share of adjusted net investment income for Q4 2025[13] - Total investment income for Q4 2024 was $56,354,000, with a net investment income of $24,171,000, representing a decrease from Q3 2025's $26,839,000[18] - The company reported a net increase in net assets resulting from operations of $17,385,000 in Q4 2025, compared to $23,903,000 in Q3 2025[18] - Net Investment Income for Q4 2025 was reported at $24,028, down from $24,171 in Q4 2024, indicating a decrease of approximately 0.6%[88] - Interest income increased from $45,697 in Q4 2024 to $60,721 in Q4 2025, representing a growth of about 32.9%[88] Portfolio and Investments - Total fair value of the portfolio increased to $2.5 billion across 165 portfolio companies with a weighted average yield of 10.1%[13] - Record originations during the quarter amounted to $404.7 million, with a weighted average yield of 8.8%[13] - New investment fundings totaled $404,746,000 in Q4 2025, with first lien debt accounting for $389,055,000 of this amount[23] - The number of investments in the portfolio was 229, with an average exposure by portfolio company of $97 million[27] - First lien debt constituted 83.7% of the total investment portfolio in Q4 2025, while second lien debt remained stable at 3.9%[20] Dividends and Shareholder Returns - Declared a quarterly dividend of $0.40 for Q1 2026, equating to an annualized dividend yield of 12.8%[13] - The annualized dividend yield to CGBD was reported at 15.3%[30] - As of Q4 2025, CGBD had an estimated $53.4 million or $0.74 per share of spillover income available to support quarterly dividends[49] - The company repurchased $13.9 million of shares in Q4, with an additional $14.0 million planned for 2026, totaling $27.9 million[49] Financial Position and Ratios - NAV per share decreased to $16.26 as of December 31, 2025, from $16.36 as of September 30, 2025[13] - Total assets increased to $2,790,167,000 in Q4 2025, up from $2,574,677,000 in Q2 2025, while total liabilities rose to $1,622,779,000[20] - The statutory debt to equity ratio increased to 1.32x in Q4 2025, reflecting a higher leverage position compared to previous quarters[20] - CGBD's net financial leverage stood at 2.89x, with an effective cost of debt of SOFR +1.60%[30] Joint Ventures and Strategic Initiatives - Entered into a new joint venture, Structured Credit Partners JV, LLC, with initial equity capital commitments of $600 million, including $150 million from Carlyle Secured Lending[16] - Structured Credit Partners JV, LLC ("SCP") is capitalized with $600 million of equity commitments from BDCs managed by Carlyle and Sixth Street[57] - SCP is expected to generate 400-500 basis points of incremental CLO return driven by no management or incentive fees at the JV or underlying CLOs[59] - Carlyle has a demonstrated track record managing CLOs over multiple credit cycles, managing $50 billion in 100+ CLOs across the U.S. and Europe[67] Asset Quality and Non-Accrual Investments - Non-accrual investments remained relatively flat at 1.8% of the total portfolio based on amortized cost as of December 31, 2025[13] - Non-accrual investments represented 1.2% of the total portfolio, indicating a stable performance in asset quality[27] - Non-accrual investments represented 1.2% of total investments at fair value, an increase from 1.0% in the prior period[43] Growth Metrics - Total Assets increased from $1,925,993 in Q4 2024 to $2,790,167 in Q4 2025, representing a growth of approximately 44.8%[86] - Total Investments at Fair Value rose from $1,803,543 in Q4 2024 to $2,463,922 in Q4 2025, an increase of about 36.6%[87] - Cash, cash equivalents, and restricted cash saw a significant increase from $56,575 in Q4 2024 to $76,493 in Q4 2025, marking a growth of 35.1%[86] - Total Liabilities increased from $1,020,789 in Q4 2024 to $1,622,779 in Q4 2025, which is an increase of approximately 59.0%[87] - Net Assets decreased from $855,204 in Q4 2024 to $1,167,388 in Q4 2025, reflecting a decline of about 36.5%[87]

MercadoLibre, Inc. Letter to Shareholders Q4'25 Results The past year showed that Mercado Libre's ecosystem is stronger than ever. Customer satisfaction reached new highs, with record Net Promoter Scores (NPS) across Commerce and Fintech in Brazil, Mexico and Argentina. This underscores the importance and effectiveness of our investments to capture structural growth opportunities across the region. Our focus on customer experience translated into strong financial performance, with revenue growth of 45% YoY ...

Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of $441.1 million[5]. - OJEMDA net revenue for Q3 2025 was $38.5 million, up from $20.1 million in Q3 2024, representing a 91.5% increase[42]. - Total revenue for the nine months ended September 30, 2025, was $104.5 million, compared to $102.0 million for the same period in 2024, showing a 2.5% increase[42]. - The company reported a net loss of $19.7 million for Q3 2025, compared to a net income of $37.0 million in Q3 2024[42]. - Research and Development expenses for the nine months ended September 30, 2025, were $107.2 million, down from $165.9 million in 2024, a decrease of 35.4%[42]. - Selling, General and Administrative expenses for the nine months ended September 30, 2025, were $86.4 million, slightly up from $85.7 million in 2024[42]. Product Development and Approval - OJEMDA received FDA approval in April 2024 for pediatric patients aged 6 months and older with specific BRAF alterations[4]. - The company plans to advance the Emi-Le program with a path toward registration and has acquired Mersana Therapeutics[5]. - The pivotal Phase 3 trial of tovorafenib in front-line pediatric low-grade glioma (pLGG) is expected to complete enrollment in 1H 2026, with topline data expected mid-2027[31]. - The company plans to complete FIREFLY-2 trial enrollment in the first half of 2026, enabling mid-2027 data readout and potential approval in 2028[43]. - The company anticipates delivering Phase 1 clinical data for Emi-Le by mid-2026 and progressing to later-stage development[43]. - DAY301 is a next-generation antibody-drug conjugate (ADC) targeting PTK7, with Phase 1a data expected in 2H 2026[37]. Market Opportunity and Growth - The company aims to solidify OJEMDA as the second-line standard of care (SOC) in relapsed or refractory pediatric low-grade glioma (pLGG) and expand its market opportunity[5]. - The company anticipates a revenue opportunity exceeding $1 billion across three high unmet need indications[7]. - The number of treatment decisions for relapsed or refractory pediatric low-grade glioma (pLGG) is approximately 1,100 annually, with significant room for market share growth for OJEMDA[14]. - OJEMDA's estimated net product revenues for Q4 2025 are projected to be $52.8 million, reflecting a 37% growth compared to Q3 2025 and a 172% increase from 2024[15]. - The expected net product revenue for OJEMDA in 2026 is estimated to be between $225 million and $250 million, indicating over 50% growth compared to 2025[16]. - OJEMDA has achieved a 60% increase in 2L adoption over the past 12 months, with a growing number of healthcare providers selecting it as their treatment of choice[17]. - The company anticipates a significant increase in prescribing accounts, with 28% sequential growth in accounts treating four or more patients[18]. - OJEMDA's commercial execution is expected to drive strong growth in 2026, supported by favorable payer dynamics and a solidified position as the second-line standard of care[16]. Clinical Data and Efficacy - OJEMDA's median duration of response is reported at 19.4 months, with 77% of patients treatment-free for at least 12 months following 24 months of therapy[12]. - 75% of patients in the Expanded Access Program (EAP) who reached 24 months on OJEMDA continued treatment, demonstrating strong persistency[17]. - The Phase 2 FIREFLY-1 trial reported a 53% overall response rate (ORR) among patients, with 58% completing 26 or more treatment cycles[23]. - Median tumor size change from baseline after the last dose was -51% at 3 months and -55% at 6 months post-treatment[26]. - All 8 patients receiving OJEMDA retreatment were still on therapy at the time of data cutoff, with a median change in tumor size of -38.3%[27]. - In the updated 3-year analysis, 38 patients had RAPNO-defined progressive disease (PD) while on OJEMDA[26]. - No new safety signals were observed in the 3-year update, with 66% of treatment-related adverse events (TRAEs) being grade ≥3[29]. - 77% of 39 patients were treatment-free for at least 12 months, with the median treatment-free interval not yet reached[28]. Intellectual Property - The patent portfolio for OJEMDA includes a composition of matter patent extending to mid-2036, with additional protections potentially extending into the 2040s[20]. Strategic Partnerships - The company is focused on global commercial expansion through partnerships, including a license agreement with Ipsen for OJEMDA outside the U.S.[6]. - The company aims to expand OJEMDA globally, extending its commercial opportunity through collaboration with Ipsen[43].

Exhibit 99.1 eXp World Holdings Reports Q4 and Full-Year 2025 Results BELLINGHAM, Wash. — February 24, 2026 — eXp World Holdings, Inc. (Nasdaq: EXPI) (the "Company," "eXp" or "we"), the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. "2025 was a defining year for eXp Realty, validating our belief that transparency and agent empowerment are the only sustainable paths forward," said Leo Pare ...

Revenue Performance - Total net revenues for 2025 were $3,931 million, a 10% increase from $3,586 million in 2024[253] - Semiconductor market revenues increased by $198 million, or 13%, in 2025, driven by higher sales in logic and foundry applications[257] - Electronics and packaging market revenues rose by $189 million, or 20%, in 2025, primarily due to increased sales of chemistry and equipment[259] - Specialty industrial market revenues decreased by $42 million, or 4%, in 2025, mainly due to lower sales to industrial customers[265] - Approximately 81% of total net revenues in 2025 came from international markets, up from 78% in 2024[266] - International net revenues reached $3.2 billion in 2025, up from $2.8 billion in 2024, with a notable $155 million increase in sales to China[303] - Product revenues increased by $312 million (10.0%) to $3.436 billion in 2025, driven by a $206 million increase in the electronics and packaging market and a $146 million increase in the semiconductor market[301] - Service revenues rose by $33 million (7.1%) to $495 million in 2025, primarily due to increased revenues in the semiconductor market[302] Market Segment Analysis - The semiconductor market represented 43% of total net revenues in 2025, compared to 42% in 2024[256] - The electronics and packaging market accounted for 28% of total net revenues in 2025, up from 26% in 2024[259] - The specialty industrial market comprised 29% of total net revenues in 2025, down from 32% in 2024[265] Financial Management - Bad debt expense was immaterial in each period presented, indicating effective credit management despite potential customer payment issues[277] - A valuation allowance of $72 million was decreased in 2025, primarily related to foreign interest and net operating loss carryforwards, indicating improved realizability of deferred tax assets[294] - The company uses derivative instruments for risk management, including foreign exchange forward contracts and interest rate swaps, to mitigate market risks[296] - Changes in market conditions could increase the likelihood of recording impairment charges for goodwill and intangible assets, necessitating ongoing monitoring[293] Expenses and Profitability - Gross profit margin decreased to 46.7% in 2025 from 47.6% in 2024, primarily due to higher duty and tariff costs and unfavorable product mix[305] - Research and development expenses increased by $28 million (10.3%) to $299 million in 2025, mainly due to higher compensation-related costs[309] - Selling, general and administrative expenses rose by $50 million (7.4%) to $724 million in 2025, primarily driven by increased compensation-related costs[313] - Interest expense decreased by $65 million (24.7%) to $198 million in 2025, attributed to the issuance of $1.4 billion in Convertible Notes and lower interest rates from loan amendments[319] - Loss on extinguishment of debt was $10 million in 2025, a decrease from $57 million in 2024, due to voluntary prepayments and loan repricing[320] Cash Flow and Financing Activities - Net cash provided by operating activities for 2025 was $645 million, resulting from net income of $295 million, including non-cash charges of $275 million[335] - Net cash used in investing activities for 2025 was $145 million, primarily for capital expenditures of $148 million related to new facility additions in Malaysia and China[337] - Net cash used in financing activities for 2025 was $562 million, including normal quarterly debt payments and voluntary debt prepayments totaling $451 million[338] - The company repurchased approximately 546,000 shares of common stock for a total consideration of $45 million in 2025[341] - The Board of Directors declared a quarterly cash dividend of $0.25 per share to be paid on March 6, 2026, to shareholders of record as of February 23, 2026[343] Debt and Credit Facilities - As of December 31, 2025, the principal outstanding on the Term Loan Facility was $2.9 billion, with a weighted average interest rate of 5.4%[347] - The company made a voluntary prepayment of approximately $1.3 billion on the USD Tranche B loan, reducing the principal from $2.2 billion to $914 million[355] - The company completed a private offering of $1.4 billion in convertible senior notes due 2030, with a coupon rate of 1.25% per annum[356][358] - The company issued €1.0 billion in senior notes due 2034, with an interest rate of 4.250% per annum[367][370] - As of December 31, 2025, the notional value of interest rate swap agreements was $1.9 billion[382] Inventory and Asset Management - Excess and obsolete inventory expense was $45 million, $56 million, and $64 million for 2025, 2024, and 2023, respectively, with 2023 charges partly due to a product line discontinuation[278] - Warranty costs are estimated based on historical repair costs, with obligations ranging from 12 to 36 months, impacting short-term and long-term liabilities[279] - The company has purchase commitments for certain inventory components and other equipment totaling approximately $490 million as of December 31, 2025[389] Taxation - The provision for income taxes for 2025 was $9 million, with an effective tax rate of 2.9%, while 2024 had a benefit of $(10) million with an effective tax rate of (5.7)%[323] - Total gross unrecognized tax benefits as of December 31, 2025, were $95 million, up from $94 million in 2024, mainly due to income tax reserves related to intercompany transactions[325]